Miyu Watanabe - Publications

Pre-CAR-HEMATOTOX at Leukapheresis Predicts Delayed Platelet Recovery After Idecabtagene Vicleucel in Multiple Myeloma.

Journal: Clinical lymphoma, myeloma & leukemia

Published: June 15, 2026

Real-world outcomes of idecabtagene vicleucel in relapsed/refractory multiple myeloma: A single-centre experience.

Journal: British journal of haematology

Published: January 28, 2026

Impact of Intensive Cyclophosphamide-Containing Multi-Agent Bridging Therapy on Outcomes after Idecabtagene Vicleucel in Multiple Myeloma.

Journal: Transplantation and cellular therapy

Published: January 19, 2026

Prognostic significance of cardiac biomarkers in patients with AL amyloidosis treated with a daratumumab-based regimen.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: January 06, 2026

Treatment Discontinuation After Achieving MRD Negativity in Multiple Myeloma in the Pre-BCMA Era: A Prospective, Single-Centre Study.

Journal: EJHaem

Published: January 03, 2026

Outcomes of elranatamab in relapsed/refractory multiple myeloma: prognostic impact of monocyte count, MyCARe, and R2-ISS.

Journal: International journal of hematology

Published: September 27, 2025

Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients With Multiple Myeloma Receiving Elranatamab.

Journal: EJHaem

Published: August 29, 2025

Can baseline cytomegalovirus IgG titers predict cytomegalovirus reactivation after ide-cel therapy?

Journal: Blood advances

Published: May 16, 2025

Cytomegalovirus Retinitis During Idecabtagene Vicleucel Therapy in Patients With Relapsed/Refractory Multiple Myeloma.

Journal: Transplant infectious disease : an official journal of the Transplantation Society

Published: February 28, 2025

TRBP modulates RLR signaling by inhibiting PKR-mediated antiviral stress granule formation.

Journal: Scientific reports

Published: February 12, 2025